GlassScriptPhysician profile
Andrew M Dewitt
NPI 1396733275
$3,553.09
in general payments reported to CMS, 2019-2025
29 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $257 · 2021: $30.39 · 2022: $512 · 2023: $1,200 · 2024: $625 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $734.99 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $511.32 | 2022-2025 | Nuzyra |
| Davol INC. | $314.52 | 2020-2024 | Phasix Mesh |
| Lilly USA, LLC | $200.34 | 2024-2025 | Zepbound |
| Teleflex LLC | $193.11 | 2023 | Titan Sgs Standard Gastric Stapler |
| Ethicon US, LLC | $172.92 | 2019-2025 | Vistaseal, Echelon; Endopath |
| Intra-Sana Laboratories | $139.63 | 2021-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Tela Bio, INC. | $138.78 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Acell, INC. | $119.28 | 2020 | |
| Conmed Corporation | $115.38 | 2023 | Airseal |
| Integra Lifesciences Corporation | $111.36 | 2022-2023 | Durasorb Monofilament Mesh, Integra, Omnigraft |
| Novo Nordisk INC | $103.38 | 2020-2023 | |
| Osiris Therapeutics INC. | $78.67 | 2019 | |
| Baxter Healthcare | $74.77 | 2019-2020 | |
| Kerecis Limited | $62.66 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $56.32 | 2024-2025 | Voquezna |
| Medtronic, INC. | $51.26 | 2022-2024 | Dextile, Reliatack |
| Vertex Pharmaceuticals Incorporated | $49.78 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $47.17 | 2023 | Gore Synecor Biomaterial |
| Currax Pharmaceuticals LLC | $46.46 | 2024-2025 | Contrave |
| Shield Therapeutics INC | $42.21 | 2022-2024 | |
| Solventum Corporation | $31.63 | 2025 | V.A.C. Veraflo, Prevena, Activ.A.C. |
| Tei Biosciences INC | $26.64 | 2019 | |
| Endo Pharmaceuticals INC. | $25.69 | 2019 | |
| Daiichi Sankyo INC. | $24.92 | 2024 | Enhertu |
| Avita Medical Americas, LLC | $22.74 | 2025 | Recell, Cohealyx, Permeaderm |
| Allergan, INC. | $22.36 | 2022 | |
| Covidien LP | $21.43 | 2019 | |
| Standard Bariatrics, INC. | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.